actr087
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02776813)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFRSF9 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- actr087
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03680560 | Phase 1 | Dec 31, 2018 | Cogent Biosciences |
| NCT03266692 | Phase 1 | Feb 22, 2018 | Cogent Biosciences, Seattle Genetics |
| NCT02776813 | Phase 1 | Aug 1, 2016 | Cogent Biosciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cogent Biosciences | For profit | 3 | 3 | 1 | 2016 |
| Seattle Genetics | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1